Shayna Sarosiek, Uriel Suarez, Maria Fernandez-Turizo, Kristopher A Sarosiek, Jorge J Castillo
{"title":"BCL-2抑制Waldenström巨球蛋白血症和边缘区淋巴瘤。","authors":"Shayna Sarosiek, Uriel Suarez, Maria Fernandez-Turizo, Kristopher A Sarosiek, Jorge J Castillo","doi":"10.1111/bjh.70208","DOIUrl":null,"url":null,"abstract":"<p><p>Marginal zone lymphoma (MZL) and Waldenström macroglobulinaemia (WM) are B-cell lymphomas characterized by an indolent disease course. However, both are incurable with current standard treatments. Therefore, additional therapies are certainly needed. BCL-2 inhibition has been a welcome addition to the treatment armamentarium for haematological malignancies. The BCL-2 inhibitor venetoclax is approved by the Food and Drug Administration and the European Medicines Agency for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia and is endorsed by the National Comprehensive Cancer Network for the treatment of WM and mantle cell lymphoma. In this review, we provide an overview of the current understanding of the BCL-2 apoptotic pathway and its impact on the development and maintenance of haematological cancers. We also summarize the preclinical and ongoing clinical experience with BCL-2 inhibitors, such as venetoclax, sonrotoclax, lisaftoclax and LOXO-338. BCL-2 inhibitors have emerged as safe and effective treatment options for treating patients with MZL and WM.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BCL-2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma.\",\"authors\":\"Shayna Sarosiek, Uriel Suarez, Maria Fernandez-Turizo, Kristopher A Sarosiek, Jorge J Castillo\",\"doi\":\"10.1111/bjh.70208\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Marginal zone lymphoma (MZL) and Waldenström macroglobulinaemia (WM) are B-cell lymphomas characterized by an indolent disease course. However, both are incurable with current standard treatments. Therefore, additional therapies are certainly needed. BCL-2 inhibition has been a welcome addition to the treatment armamentarium for haematological malignancies. The BCL-2 inhibitor venetoclax is approved by the Food and Drug Administration and the European Medicines Agency for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia and is endorsed by the National Comprehensive Cancer Network for the treatment of WM and mantle cell lymphoma. In this review, we provide an overview of the current understanding of the BCL-2 apoptotic pathway and its impact on the development and maintenance of haematological cancers. We also summarize the preclinical and ongoing clinical experience with BCL-2 inhibitors, such as venetoclax, sonrotoclax, lisaftoclax and LOXO-338. BCL-2 inhibitors have emerged as safe and effective treatment options for treating patients with MZL and WM.</p>\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bjh.70208\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.70208","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
边缘带淋巴瘤（MZL）和Waldenström巨球蛋白血症（WM）是b细胞淋巴瘤，其特点是病程缓慢。然而，用目前的标准治疗方法，这两种疾病都无法治愈。因此，当然需要额外的治疗方法。BCL-2抑制已成为血液学恶性肿瘤治疗的一个受欢迎的补充。BCL-2抑制剂venetoclax已被美国食品和药物管理局（fda）和欧洲药品管理局（ema）批准用于治疗慢性淋巴细胞白血病和急性髓系白血病，并得到美国国家综合癌症网络（National Comprehensive Cancer Network）的认可，用于治疗WM和套细胞淋巴瘤。在这篇综述中，我们概述了目前对BCL-2凋亡途径及其对血液学癌症发展和维持的影响的理解。我们还总结了BCL-2抑制剂的临床前和正在进行的临床经验，如venetoclax、sonrotoclax、lisaftoclax和LOXO-338。BCL-2抑制剂已成为治疗MZL和WM患者的安全有效的治疗选择。
BCL-2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma.
Marginal zone lymphoma (MZL) and Waldenström macroglobulinaemia (WM) are B-cell lymphomas characterized by an indolent disease course. However, both are incurable with current standard treatments. Therefore, additional therapies are certainly needed. BCL-2 inhibition has been a welcome addition to the treatment armamentarium for haematological malignancies. The BCL-2 inhibitor venetoclax is approved by the Food and Drug Administration and the European Medicines Agency for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia and is endorsed by the National Comprehensive Cancer Network for the treatment of WM and mantle cell lymphoma. In this review, we provide an overview of the current understanding of the BCL-2 apoptotic pathway and its impact on the development and maintenance of haematological cancers. We also summarize the preclinical and ongoing clinical experience with BCL-2 inhibitors, such as venetoclax, sonrotoclax, lisaftoclax and LOXO-338. BCL-2 inhibitors have emerged as safe and effective treatment options for treating patients with MZL and WM.
期刊介绍：
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
